Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 21;29(23):3574-3594.
doi: 10.3748/wjg.v29.i23.3574.

Recent advances in treatment of nodal and gastrointestinal follicular lymphoma

Takuya Watanabe  1
Affiliations
Editorial

Recent advances in treatment of nodal and gastrointestinal follicular lymphoma

Takuya Watanabe. World J Gastroenterol. .

Abstract

Follicular lymphoma (FL) is the most common low-grade lymphoma, and although nodal FL is highly responsive to treatment, the majority of patients relapse repeatedly, and the disease has been incurable with a poor prognosis. However, primary FL of the gastrointestinal tract has been increasingly detected in Japan, especially due to recent advances in small bowel endoscopy and increased opportunities for endoscopic examinations and endoscopic diagnosis. However, many cases are detected at an early stage, and the prognosis is good in many cases. In contrast, in Europe and the United States, gastrointestinal FL has long been considered to be present in 12%-24% of Stage-IV patients, and the number of advanced gastrointestinal cases is expected to increase. This editorial provides an overview of the recent therapeutic advances in nodal FL, including antibody-targeted therapy, bispecific antibody therapy, epigenetic modulation, and chimeric antigen receptor T-cell therapy, and reviews the latest therapeutic manuscripts published in the past year. Based on an understanding of the therapeutic advances in nodal FL, we also discuss future possibilities for gastroenterologists to treat gastrointestinal FL, especially in advanced cases.

Keywords: Antibody-based therapy; Bispecific antibody therapy; Chimeric antigen receptor-T cell therapy; Epigenetic modulator; Nodal and gastrointestinal follicular lymphoma; Phosphatidylinositol-3 kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

References

    1. The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int. 2000;50:696–702. - PubMed
    1. Jaffe ES, Harris NL, Stein H, Vardiman J. World Health Organization Classification of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues. 2001. [cited 20 April 2023]. Avaliable from: https://tumourclassification.iarc.who.int/welcome/
    1. Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, Tomotaka S, Morton LM, Weisenburger DD, Matsuo K. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–545. - PMC - PubMed
    1. d'Amore F, Christensen BE, Brincker H, Pedersen NT, Thorling K, Hastrup J, Pedersen M, Jensen MK, Johansen P, Andersen E. Clinicopathological features and prognostic factors in extranodal non-Hodgkin lymphomas. Danish LYFO Study Group. Eur J Cancer. 1991;27:1201–1208. - PubMed
    1. Cirillo M, Federico M, Curci G, Tamborrino E, Piccinini L, Silingardi V. Primary gastrointestinal lymphoma: a clinicopathological study of 58 cases. Haematologica. 1992;77:156–161. - PubMed

Publication types

MeSH terms

Substances